Lung cancer remains one of the greatest medical challenges with nearly 1.5 million new
cases worldwide each year and a growing tobacco epidemic in the developing world. This …

Historically, the prognosis for individuals diagnosed with lung cancer has been bleak.
However, the past 10 years have seen important advances in treatment and diagnosis which …

Lung cancer remains the most common cause of cancer-related death among men and
women worldwide. Incremental and significant advances in available systemic treatments …

Increasingly, basic research is being translated into clinical benefits for patients. Recent
studies have shed more light on the clinical use of targeted therapies such as tyrosine …

Progress has been made in the treatment of lung cancer over the past 40 years, albeit at a
modest pace. Cytoxic chemotherapy has improved 5-year survival rates when added to …

Thoroughly revised and updated, this Fourth Edition is the most comprehensive, current
reference on lung cancer, with contributions from the world's foremost surgeons, radiation …

In recent years, many personalized treatments have been developed for NSCLC (non-small-
cell lung cancer) patients. Among these, gefitinib, erlotinib, and afatinib are selective …

Lung cancer is an aggressive disease that is the leading cause of death from cancer in both
males and females. Non–small cell lung cancer accounts for approximately 75% of all cases …

There have been remarkable advances in the targeted treatment of advanced non-small cell
lung cancer (NSCLC) over the past several years. Survival outcomes are steadily improving …

Lung cancer management that is individualized for age, comorbidities, cancer type, cancer
stage, and patient preference has long been a cornerstone of management. New to this …